A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Pulmonary Hypertension

Mean change from baseline to Week 24 in PVR as measured by right heart catheterization (RHC) in participants with baseline PVR ≥3 Wood units who received TX000045 compared with those who received placebo, In participants who received TX000045 compared with placebo, describe: • Incidence of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) • Incidence of clinically significant changes from baseline in laboratory assessments, 12-lead electrocardiogram (ECG), vital sign assessments, and physical examinations

Mean change from baseline to Week 24 in PVR as measured by right heart catheterization (RHC) in participants with baseline PVR ≥3 Wood units who received TX000045 compared with those who received placebo

No related papers found yet.

Austria, Belgium, Bulgaria, Germany, Latvia, Poland, Portugal, Romania, Spain